Drug Profile

SC 0023

Alternative Names: SC-0023

Latest Information Update: 07 Oct 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Sensory Cloud
Class Antitussives
Mechanism of Action Ion channel antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Cough

Most Recent Events

23 Sep 2025 Discontinued - Phase-II for Cough in Saudi Arabia (unspecified route)
20 Aug 2025 Efficacy and adverse events data from the phase IIa REACH trial in Cough released by Sensory Cloud
20 Aug 2025 Sensory Cloud in collaboration with the Professor Kian Fan Chung plans the REACH 2 trial for Cough in the United Kingdom in 2025

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com